Právní předpis byl sestaven k datu 02.08.2025.
Zobrazené znění právního předpisu je účinné od 01.10.2015.
Nařízení vlády, kterým se mění nařízení vlády č. 463/2013 Sb., o seznamech návykových látek
243/2015 Sb.
Účinnost Čl. III
243
NAŘÍZENÍ XXXXX
xx dne 14. xxxx 2015,
xxxxxx xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx
Xxxxx nařizuje xxxxx §44c odst. 1 xxxxxx x. 167/1998 Xx., o xxxxxxxxxx látkách a x xxxxx některých xxxxxxx xxxxxx, xx xxxxx xxxxxx x. 273/2013 Xx.:
Čl. X
Xxxxxxx x. 4 x nařízení xxxxx č. 463/2013 Sb., x xxxxxxxxx xxxxxxxxxx látek, xxx:
"Xxxxxxx č. 4 x xxxxxxxx xxxxx x. 463/2013 Xx.
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx název xxxx xxxxxx xxxxx |
Xxxxxxxx xxxxx xxxxx IUPAC |
Poznámka |
|
AH-7921 |
3,4-dichlor-N-{[1-(dimethylamino)cyclohexyl)]methyl}benzamid |
||
|
AM-2201 |
[1-(5-fluorpentyl)-1H-indol-3-yl](naftalen-1-yl)methanon |
||
|
5-AP1 |
5-(2-aminopropyl)indol |
||
|
APINACA |
N-(adamantan-1-yl)-1-pentyl-1H-indazol-3-karboxamid |
||
|
bk-PMA |
2-amino-1-(4-methoxyfenyl)propan-1-on |
||
|
bk-PMMA |
1-(4-methoxyfenyl)-2-(methylamino)propan-1-on |
||
|
25B-NBOMe |
2-(4-brom-2,5-dimethoxyfenyl)-N-[(2-methoxyfenyl)methyl]ethanamin |
||
|
Brolamfetamin |
DOB |
(2RS)-1-(4-brom-2,5-dimethoxyfenyl)propan-2-amin |
|
|
Bromo-Dragonfly |
1-(8-brombenzo[1,2b:4,5-b´]difuran-4-yl)propan-2-amin |
||
|
Butylon |
2-(methylamino)-1-[3,4-(methylendioxy)fenyl)]butan-1-on |
||
|
Joddimethoxyfenethylamin |
2C-I |
(4-jod-2,5-dimethoxyfenethyl)amin |
|
|
25C-NBOMe |
2-(4-chlor-2,5-dimethoxyfenyl)-N-[(2-methoxyfenyl)methyl]ethanamin |
||
|
Dimethoxyethylthiofenethylamin |
2C-T-2 |
[4-(ethylsulfanyl)-2,5-dimethoxyfenethyl]amin |
|
|
Dimethoxypropylthiofenethylamin |
2C-T-7 |
[2,5-dimethoxy-4-(propylsuIfanyl)fenethyl]amin |
|
|
CP-47,497 |
2-[(1R,3S)-3-hydroxycyklohexyl]-5-(2-methyloktan-2-yl)fenol |
||
|
CRA-13 |
(naftalen-1-yl)[4-(pentyloxy)naftalen-1-yl]methanon |
||
|
DBZP |
1,4-dibenzylpiperazin |
||
|
Dielhyltryptamin |
DET |
N,N-diethyl-N-[2-(indol-3-yl)ethyl]amin |
|
|
Dimethoxyamfetamin |
DMA |
(2RS)-1-(2,5-dimethoxyfenyl)propan-2-amin |
|
|
4,4'-DMAR |
4-methyl-5-(4-methylfenyl)-4,5-dihydro-1,3-oxazol-2-amin |
||
|
Dimethylheptyltetrahydrokanabinol |
DMHP |
3-(1,2-dimethylheptyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c] xxxxxxx-1-xx |
|
|
3,4-XXXX |
1-(3,4-xxxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX |
X[2-(xxxxx-3-xx (ethyl]-N,N-dimethylamin |
|
|
DOC |
1-(4-chlor-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Dimethoxyethylamfetamin |
DOET |
(2RS)-1-(4-ethyl-2,5-dimethoxyfenyl)propan-2-amin |
|
|
DOl |
1-(4-jod-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Eticyklidin |
PCE |
N-ethyl-1-fenylcyklohexylamin |
|
|
Etryptamin |
3-(2-aminobutyl)indol |
||
|
4-FA |
1-(4-fluorfenyl)propan-2-amin |
||
|
5F-AKB48 |
N-(adamantan-1-yl)-1-(5-fluorpentyl)-1H-indazol-3-karboxamid |
||
|
Flefedron |
1-(4-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
4-FMA |
1-(4-fluorfenyl)-N-methylpropan-2-amin |
||
|
3-FMC |
1-(3-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
5FUR-144 |
[1-(5-fluorpentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyklopropyl)methanon |
||
|
251-NBOMe |
2-(4-jod-2,5-dimethoxyfenyl)-N-[(2-methoxyfenyl)methyl]ethanamin |
||
|
JWH-018 |
(naftalen-1-yl)(1-pentyl-1H-indol-3-yl)methanon |
||
|
JWH-073 |
(1-butyl-1H-indol-3-yl)(naftalen-1-yl)methanon |
||
|
JWH-081 |
(4-methoxynaftalen-1-yl)(1 -xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
XXX-122 |
(4-xxxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-x)xxxxxxxx |
||
|
XXX-200 |
[1-(2-xxxxxxxxxxxxxx)-1X-xxxxx-3-xx](xxxxxxxx-1-xx)xxxxxxxx |
||
|
XXX-250 |
2-(2-xxxxxxxxxxxx)-1-(1-xxxxxx-1X-xxxxx-3-xx)xxxxx-1-xx |
||
|
XXX-398 |
(4-xxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
Xxxxxxxx |
(2X)-2-xxxxx-1-xxxxxxxxxxx-1-xx |
||
|
(+)-Xxxxxxxx |
XXX, XXX-25 |
(+)-8β-(3,3-xxxxxxxxxxxxxx)-6-xxxxxx-9,10-xxxxxxxxxxxxxxxx |
|
|
4-Xxxxxxxxxxxx |
(2XX)-1-(4-xxxxxxxxxxx)xxxxxx-2-xxxx |
||
|
XXXX |
1-xxxxxx-4-xxxxxxxxxxxxxxx |
||
|
xXXX |
1-(3-xxxxxxxxxx)xxxxxxxxx |
||
|
XXXX |
5,6-(xxxxxxxxxxxxx)xxxxx-2-xxxx |
||
|
XXXX |
1-[3,4-(xxxxxxxxxxxxx)xxxxx]-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
3-XXX |
2-(xxxxxxxxxx)-1-(3-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
4-XXX |
2-(xxxxxxxxxx)-1-(4-xxxxxxxxxxx)-xxxxxx-1-xx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-(4-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxx |
3,4,5-xxxxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxx |
Xxxxxxx |
(2XX)-1-xxxxx-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
3-XXX |
2-(xxxxxxxxxxx(-1-(3-xxxxxXxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-1-[5-xxxxxxx-3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxx |
(±)-5-xxxxx-4-xxxxxx-4,5-xxxxxxxxxxxxx-2-xxxxx |
||
|
Xxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-X-xxxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
3-XxX-XXX |
1-[1-(3-xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxxxxx |
||
|
xxxxxxxxxxxxx |
2-(xxxxxxxxxx)-2-(3-xxxxxxxxxxxx)xxxxxxxxxxxx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-1-xx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
4-XXX |
(2XX)-1-[4-(xxxxxXxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxx |
1-(xxxxxxxx-2-xx)-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX, MDEA |
(2RS)-N-ethyl-1-[3,4-(methylendioxy)fenyllpropan-2-amin |
|
|
Hydroxytenamfetamin |
(2RS)-N-hydroxy-1-[3,4-(methylendioxy)fenyl]propan-2-amin |
||
|
Paraliexyl |
3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol |
||
|
pentedron |
1-fenyl-2-(methylainino)pentan-1-on |
||
|
pFPP |
1-(4-fluorfenyl)piperazin |
||
|
Methoxyamfetamin |
PMA |
(2RS)-1-(4-methoxyfenyl)propan-2-amin |
|
|
Methoxymetamfetamin |
PMMA |
1-(4-methoxyfenyl)-N-methylpropan-2-amin |
|
|
Psilocybin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-yl-dihydrogen-fosfát |
||
|
Psilocin |
Psilotsin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-ol |
|
|
Rolicyklidin |
PHP, XXXX |
1-(1-xxxxxxxxxxxxxxx)xxxxxxxxxx |
|
|
α-XXX |
1-xxxxx-2-(xxxxxxxxxx-1-xx)-1-xxxxxx-1-xx |
||
|
Xxxxxxxxxx X |
xxxxxx-(2XX,4xX,6xX,7X,9XX,10xXX,10xX)-9-xxxxxxx-2-(xxxxx-3-xx)-6x, 10b-dimethyl-4,10-dioxododekahydro-1H-benzo[f]isochromen-7-karboxylát |
||
|
Dimethoxymetamfetamin |
STP, XXX |
(2XX)-1-(2,5-xxxxxxxxx-4-xxxxxxxxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
(2XX)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
1-[1-(2-xxxxxxx)xxxxxxxxxx]xxxxxxxxx |
|
|
XXXXX |
1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX |
Δ6x(10x)-,Δ6x(7)-,Δ7-,Δ8-,Δ10-,Δ9(11)-xxxxxxxxxxxxxxxxxxxx x jejich stereoizomery |
|
|
Trimethoxyamfetamin |
TMA |
(2RS)-1-(3,4,5-trimethoxyfenyl)propan-2-amin |
|
|
Trimethoxyamfetamin-2 |
TMA-2 |
(2RS)-1-(2,4,5-trimethoxyfenyl)propan-2-amin |
|
|
UR-144 |
(1-pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethylcyklopropyl)methanon |
Včetně xxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xx xxxxxxxx xxxxxxx, xxxxxxxxx x xxxxx xxxxxxx xx xxxxx případech, kdy xxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxx x xxxx psychotropních xxxxx xxxxxxxxx x tomto xxxxxxx xx xxxxx xxxxxxxxx, kdy mohou xxxxxxxxx.".
Xx. II
Toto xxxxxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx 98/34/ES xx xxx 22. xxxxxx 1998 x postupu xxx poskytování xxxxxxxxx x xxxxxxx norem x xxxxxxxxxxx xxxxxxxx x xxxxxxxx xxx xxxxxx xxxxxxxxxx xxxxxxxxxxx, x platném xxxxx.
Xx. XXX
Xxxxxxxx
Xxxx xxxxxxxx xxxxxx účinnosti xxxx 1. xxxxx 2015.
&xxxx;Xxxxxxxx xxxxx:
Xxx. Sobotka v. x.
&xxxx;Xxxxxxx zdravotnictví:
MUDr. Xxxxxxx, XXX, v. r.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 243/2015 Sb. xxxxx xxxxxxxxx dnem 1.10.2015.
Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.